CD8A and neoplasm: The hydrogel, injected into the bone defect after primary tumor resection, can sustainably prolong the release of αPD-L1 and vismodegib for up to 2 weeks, enhancing the activity of activated CD8+ T cells that have been suppressed by invading tumor cells.